期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

强化他汀治疗在急性冠状动脉综合征中的应用研究新进展 被引量：5

下载PDF
导出
摘要 急性冠状动脉综合征（acute coronary syndromes，ACS）是以冠状动脉粥样硬化斑块破裂或侵蚀，继发完全或不完全闭塞性血栓形成为病理基础的一组临床综合征，包括急性ST段抬高型心肌梗死（STEMI）、急性非ST段抬高型心肌梗死（NSTEMI）和不稳定型心绞痛（UA）。因其发病急、致死致残率高而引起临床广泛关注。目前ACS的治疗原则为在规范的抗血小板聚集、
作者 苏亚坤 王涛 姜志安
机构地区 河北医科大学第三医院心血管二科
出处 《疑难病杂志》 CAS 2014年第6期657-659,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 强化他汀 急性冠状动脉综合征 多效性
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献4

二级参考文献44

  • 1Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量：43
  • 2高润霖,吴宁,胡大一,等.心血管病治疗指南和建议[M].北京:人民军医出版社,2005:261-315
  • 3Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 4LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 5Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 6Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 7Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 8Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 9Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 10Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.

共引文献2374

同被引文献44

  • 1Leeson T G, Bulugahapitiya S. Contrast-induced nephrop- athy[ J]. AJR Am J Roentgenol, 2004, 183 (6) : 1673- 1689.
  • 2Rao Q A, Newhouse J H. Risk of nephropathy after intra- venous administration of contrast material: a critical liter- ature analysis [ J ]. Radiology, 2006,239 ( 2 ) : 392-397.
  • 3Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease [ J]. J Am Coll Cardiol, 2014,63 ( 1 ) :62-70.
  • 4Kushner F G, Hand M, Smith S C Jr, et al. 2009 fo- cused updates : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction ( upda- ting the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary in- tervention (updating the 2005 guideline and 2007 focused update) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ]. Circulation, 2009, 120 ( 22 ) : 2271-2306.
  • 5Ma Y C, Zuo L, Chen J H, et al. Modified glomerular filtration rate estimating equation for chinese patients with chronic kidney disease[J]. J Am Soc Nephrol, 2006,17 (10) :2937-2944.
  • 6American Diabetes Association. Diagnosis and classifica- tion of diabetes mellitus [ J ]. Diabetes Care, 2012,35 ( Suppl 1 ) : $64-$71.
  • 7Eckardt K U, Berns J S, and classification of CKD : fient prognosis-a position Rocco M V, et al. Definition the debate should be about pa- statement from KDOQI and KDIGO[ J]. Am J Kidney Dis, 2009,53(6) :915-920.
  • 8Schweiger M J, Chambers C E, Davidson C J, et al. Pre- vention of contrast induced nephropathy: recommenda- tions for the high risk patientundergoing cardiovascular procedures [ J ]. Catheter Cardiovasc Interv, 2007, 69 (1) :135-140.
  • 9Kunieda Y, Nakagawa K, Nishimura H, et al. HMG coa reductase inhibitor suppresses the expression of tissue fac- tor and plasminogen activator inhibitor-1 induced by an- giotensin ii in cultured rat aortic endothelial ceils [ J ]. Thromb Res, 2003,110 (4) : 227-234.
  • 10Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy [ J ]. Clin Nephrol, 2004,62(4) :273-278.

二级引证文献26

疑难病杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部